Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Details of the oral presentation are as follows: Details of the poster presentations are as follows: Title: Pharmacological and functional characterization of the first small molecule TREM2 agonist, VG-3927, for the treatment of Alzheimer's disease Presented by: Borislav Dejanovic, Ph.D., Vigil Neuroscience Date and Time: Sunday, July 28, 2024, 8:00 AM – 4:15 PM EDT (Poster location Sunday-77) About Vigil Neuroscience Vigil Neuroscience routinely posts information that may be important to investors in the ' ...